Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Lip, GYH; Nikorowitsch, J; Sehner, S; Becher, N; Bertaglia, E; Blomstrom-Lundqvist, C; Brandes, A; Beuger, V; Calvert, M; Camm, AJ; Chlouverakis, G; Dan, GA; Dichtl, W; Diener, HC; Fierenz, A; Goette, A; de, Groot, JR; Hermans, A; Lubinski, A; Marijon, E; Merkely, B; Mont, L; Ozga, AK; Rajappan, K; Sarkozy, A; Scherr, D; Schnabel, RB; Schotten, U; Simantirakis, E; Toennis, T; Vardas, P; Wichterle, D; Zapf, A; Kirchhof, P.
Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.
Eur Heart J. 2024; 45(19):1733-1737 Doi: 10.1093/eurheartj/ehae225 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Scherr Daniel
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Atrial Fibrillation - drug therapy, complications
Anticoagulants - administration & dosage, therapeutic use
Female - administration & dosage
Male - administration & dosage
Administration, Oral - administration & dosage
Age Factors - administration & dosage
Aged - administration & dosage
Sex Factors - administration & dosage
Stroke - prevention & control, epidemiology
Comorbidity - administration & dosage
Treatment Outcome - administration & dosage
Cardiovascular Diseases - prevention & control, epidemiology

Find related publications in this database (Keywords)
Atrial high-rate episodes
Device-detected atrial fibrillation
Stroke
Atrial fibrillation
CHA2DS2-VASc score
Kidney function
NOAH-AFNET 6
Anticoagulation
Bleeding
© Med Uni Graz Impressum